2.2 Pharmacokinetics and Pharmacodynamics

Pharmacodynamics and Pharmacokinetics

Pharmacodynamics is the study of what a drug does to the body. Pharmacokinetics is the study of what the body does to the drug. Together, these two concepts explain why a medication works, how quickly it takes effect, how long it lasts, and why dosing matters so much in clinical practice.

Pharmacodynamics

Drug interactions with body cells

Drugs produce their effects by interacting with specific molecular targets in the body. The four main targets are receptors, enzymes, ion channels, and transporters. Understanding which target a drug acts on helps you predict both its therapeutic effects and its side effects.

Receptors are the most common drug targets. Drugs bind to receptors on cell surfaces or inside cells, and what happens next depends on the type of drug:

• Agonists activate the receptor and produce a biological response. Morphine, for example, activates opioid receptors to produce pain relief.
• Antagonists bind to the receptor but don't activate it. Instead, they block agonists from binding. Naloxone blocks opioid receptors, which is why it reverses opioid overdoses.
• Receptor affinity describes how strongly a drug binds to its receptor. Higher affinity means the drug binds more tightly and is effective at lower concentrations.

Enzymes catalyze chemical reactions in the body, and drugs can alter their activity:

• Enzyme inhibitors block enzyme activity, reducing the production of a substance. Statins work this way by inhibiting HMG-CoA reductase, which slows cholesterol production.
• Enzyme inducers increase enzyme activity. Rifampin induces cytochrome P450 enzymes in the liver, which speeds up the metabolism of many other drugs and can reduce their effectiveness.

Ion channels control the flow of ions (like calcium, sodium, and potassium) across cell membranes:

• Channel blockers reduce ion flow. Calcium channel blockers, for instance, decrease calcium entry into cardiac and smooth muscle cells, lowering blood pressure.
• Channel openers increase ion flow. Potassium channel openers allow more potassium out of cells, which relaxes smooth muscle.

Transporters are proteins that move substances across cell membranes:

• Transporter inhibitors block this movement. SSRIs inhibit the serotonin reuptake transporter, keeping more serotonin available in the synapse.
• Transporter enhancers increase transporter activity. Probenecid enhances uric acid transport in the kidneys, promoting its excretion.

Pharmacokinetics

Pharmacokinetics covers the four processes a drug goes through in the body: absorption, distribution, metabolism, and excretion (often abbreviated as ADME). Each of these steps affects how much active drug reaches its target and for how long.

Factors in drug effectiveness

Absorption is how the drug gets from its administration site into the bloodstream. Several factors influence this:

• Route of administration (oral, IV, subcutaneous, topical, etc.). IV administration bypasses absorption entirely since the drug goes straight into the blood.
• GI factors for oral drugs: stomach pH, gut motility, and whether the patient has eaten. Food can speed up, slow down, or reduce absorption depending on the drug.
• Drug formulation matters too. Extended-release tablets dissolve more slowly than immediate-release forms.
• Bioavailability is the fraction of the administered dose that actually reaches systemic circulation. IV drugs have 100% bioavailability. Oral drugs always have less because of incomplete absorption and the first-pass effect.

Distribution is how the drug moves from the bloodstream into body tissues:

• Organs with high blood flow (heart, liver, kidneys, brain) receive drug faster than poorly perfused tissues like fat and bone.
• Many drugs bind to plasma proteins (especially albumin). Only the unbound fraction is pharmacologically active.
• The blood-brain barrier limits which drugs can reach the central nervous system. Only lipid-soluble or very small molecules cross easily.

Metabolism is the chemical alteration of the drug, primarily in the liver:

• The cytochrome P450 enzyme system is responsible for metabolizing a large proportion of drugs. Genetic variations in these enzymes explain why some patients metabolize drugs faster or slower than average.
• The first-pass effect occurs when an orally administered drug is partially metabolized by the liver before reaching systemic circulation. This is why some drugs require higher oral doses compared to IV doses, and why certain drugs (like nitroglycerin) are given sublingually to bypass it.

Excretion is how the body eliminates the drug, primarily through the kidneys:

• Renal function directly affects how quickly drugs are cleared. Patients with impaired kidney function often need dose adjustments.
• Urine pH can influence reabsorption of certain drugs in the renal tubules.
• Some drugs are also excreted through bile, lungs, or sweat.

Patient-specific factors affect every stage of ADME:

• Age (neonates and elderly patients have immature or declining organ function)
• Body weight and composition (fat-soluble drugs distribute differently in obese patients)
• Comorbidities (liver disease impairs metabolism; kidney disease impairs excretion)
• Concomitant medications (drug interactions can alter any ADME step)

Significance of drug half-life

Half-life is the time it takes for the plasma concentration of a drug to decrease by 50%. This single value tells you a lot about how to dose a medication.

• Drugs with short half-lives need more frequent dosing. Acetaminophen has a half-life of about 2-3 hours, so it's typically dosed every 4-6 hours.
• Drugs with long half-lives can be dosed less often. Fluoxetine has a half-life of 1-3 days (and its active metabolite even longer), so once-daily dosing works.

Steady-state concentration is reached when the amount of drug being administered equals the amount being eliminated. This typically takes 4-5 half-lives. Until steady state is reached, drug levels are still building up, which is why some medications (like fluoxetine) take days to weeks before full therapeutic effects appear.

Side effects vs. adverse effects

These two terms are often used interchangeably in casual conversation, but they have distinct meanings in pharmacology:

• Side effects are predictable, often dose-dependent effects that aren't the intended therapeutic goal. They're usually mild and tolerable. Antihistamines causing drowsiness or anticholinergics causing dry mouth are classic examples. Side effects are known consequences of the drug's mechanism of action.
• Adverse effects are harmful and often unexpected reactions. Some are dose-independent, meaning they can occur at any dose. Severe examples include anaphylaxis, hepatotoxicity, and cardiac arrhythmias. These can be life-threatening.

As a nurse, monitoring for both is a core responsibility:

• Assess patients regularly for expected side effects and educate them about what to watch for
• Report adverse effects promptly; dose adjustments or medication changes may be needed
• Document and report serious adverse events through proper channels (such as the FDA's MedWatch program) to contribute to ongoing drug safety surveillance

Drug tolerance and toxicity

Tolerance is a decreased response to a drug after repeated use. The patient needs higher doses to achieve the same effect. This is common with opioids and benzodiazepines, which is one reason these drug classes carry significant risk.

Tolerance develops through several mechanisms:

• Receptor downregulation: the body reduces the number or sensitivity of receptors
• Enzyme induction: the liver produces more metabolizing enzymes, clearing the drug faster
• Compensatory physiological changes: the body adjusts its own processes to counteract the drug's effects

Toxicity refers to harmful effects from excessive drug exposure. It can result from:

• Intentional or accidental overdose
• Drug accumulation (especially in patients with impaired renal or hepatic function)
• Drug interactions that increase plasma levels

There are two main types:

• Dose-dependent toxicity: severity increases predictably with higher doses (e.g., acetaminophen hepatotoxicity above 4g/day)
• Idiosyncratic toxicity: unpredictable reactions not directly related to dose, often due to genetic factors

Management of toxicity involves supportive care, administering antidotes when available (e.g., N-acetylcysteine for acetaminophen overdose, naloxone for opioid overdose), and discontinuing or adjusting the offending drug.

The therapeutic index (TI) is the ratio between the toxic dose and the therapeutic dose. A drug with a narrow therapeutic index (like warfarin, digoxin, or lithium) has a small margin between the effective dose and the toxic dose, requiring careful monitoring and precise dosing. A wide therapeutic index means there's a larger safety margin.

Drug Interactions

Drug interactions occur when one drug alters the effect of another. They can affect pharmacokinetics (changing how a drug is absorbed, distributed, metabolized, or excreted) or pharmacodynamics (changing the drug's effect at its target).

Possible outcomes include:

• Increased drug effect or toxicity (e.g., combining two CNS depressants like opioids and benzodiazepines)
• Decreased drug effect or treatment failure (e.g., rifampin inducing metabolism of oral contraceptives, reducing their effectiveness)

Common mechanisms:

• Enzyme inhibition or induction (CYP450 interactions are among the most clinically significant)
• Altered GI absorption (antacids can reduce absorption of certain antibiotics)
• Competition for the same receptor or plasma protein binding sites

Thorough medication reconciliation at every patient encounter is essential. Review all medications, including over-the-counter drugs and supplements, and monitor for signs of interactions throughout treatment.